The Impact of EGFR Mutation on Adjuvant Chemotherapy with UFT for Patients with Completely Resected, Non-Lymph Node Metastatic Non-Small Cell Lung Cancer (>2 cm): A Multicenter, Retrospective, Observational Study as Secondary Analysis of CSPOR-LC03 Study

The Impact of EGFR Mutation on Adjuvant Chemotherapy with UFT for Patients with Completely Resected, Non-Lymph Node Metastatic Non-Small Cell Lung Cancer (>2 cm): A Multicenter, Retrospective, Observational Study as Secondary Analysis of CSPOR-LC03 Study - The Impact of EGFR Mutation on Adjuvant Chemotherapy with UFT for Patients with Completely Resected, Non-Lymph Node Metastatic Non-Small Cell Lung Cancer (>2 cm): A Multicenter, Retrospective, Observational Study as Secondary Analysis of CSPOR-LC03 Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047443

Enrollment

2599

Registered

2022-04-08

Start date

2022-05-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Completely resected, non-lymph node metastatic non-small cell lung cancer (&gt

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In the CSPOR-LC03 study, data from 5005 patients with completely resected NSCLC were collected from 34 institutions in Japan. These patients were diagnosed as Pathological Stage I (T1>2 cm, TNM Classification 6th edition) and underwent lobectomy or more extensive surgical resection plus ND2a or more extensive lymphadenectomy during the period from the start month of each institution to December 31, 2013, but were not enrolled in the JCOG0707 study. By retrospective analysis of patient demographic characteristics, tumor profiles, and post-operative treatments, 2599 patients were classified as patients "who were eligible for the JCOG0707 study but were not actually enrolled." Of the 2599 patients, 74 patients were excluded because whether they received adjuvant UFT therapy was unknown, and the remaining 2525 patients will be the subjects of this observational study.

Exclusion criteria

Exclusion criteria: Patients whose status of use of adjuvant chemotherapy is unknown.

Design outcomes

Primary

Measure	Time frame
5-year recurrence-free survival (RFS) rate	—

Secondary

Measure	Time frame
5-year overall survival (OS) rate	—

Countries

Japan

Contacts

Public ContactTomohiro Miyoshi

Observational Study as Secondary Analysis of CSPOR-LC03 Study Coordinating Office Division of Thoracic Surgery, National Cancer Center Hospital East

cspor-lc03add@csp.or.jp04-7133-1111

Outcome results